Resistance-gene-guided genome mining for novel antifungal compounds
抗性基因引导的新型抗真菌化合物基因组挖掘
基本信息
- 批准号:10368095
- 负责人:
- 金额:$ 19.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-08 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAfrica South of the SaharaAmphotericin BAnabolismAntifungal AgentsAreaAspergillusAspergillus nidulansAsthmaBiologicalCandida albicansCandida aurisCatalytic DomainCell WallCessation of lifeComputersCryptococcus neoformansDatabasesDiseaseElongation FactorEngineeringEnzymesFungal GenomeFungi ModelGene ClusterGene ExpressionGenesGenomeGrowthHumanImmuneInfrastructureInstitutesIntravenousJointsLearningLogicLovastatinMalariaMammalsMedicalMetabolismMiningMycosesNatural ResistanceNatureOrgan TransplantationOrganismPathogenicityPathway interactionsPatientsPenicillinsPersonsPneumoniaProcessProductionProteinsRenaissanceResearchResistanceRoleSourceStructureSystemSystemic infectionTestingTherapeuticTimeTranslationsTuberculosisVariantbasecancer transplantationefficacy evaluationfungusgene productgenome sequencingin silicoinhibitormetabolomenovelnovel strategiespathogenpathogenic fungusresistance genesuccess
项目摘要
PROJECT SUMMARY
Approximately 1.5 million people die each year, worldwide, from systemic fungal infections. The high death toll
highlights the limitations of current treatments and, in addition, there is a growing problem with resistance to
existing antifungals. There is, thus, a compelling need for new and better antifungal agents. Surprisingly, fungi
are a good source of antifungals, the echinocandins being a prime example. The antifungals produced by fungi
are secondary metabolites (SMs)--compounds that are not essential for viability but confer a selective advantage
to the producing organism, often by inhibiting growth of its competitors. The fact that they often inhibit important
biological activities has made them a prime source of medically valuable compounds. Fungal SM biosynthetic
pathways are encoded by clusters of coordinately regulated genes. Genome projects have revealed that there
are vastly more SM gene clusters than known SMs, and, thus, that the greater fungal secondary metabolome
(all SMs made by all 1,000,000+ species of fungi) is much larger than was previously thought. To exploit the
diversity of fungal SMs efficiently, we need to be able to identify clusters that produce compounds with desired
activities. A promising approach to this end, called resistance-gene-directed genome mining, takes advantage
of the fact that some SM biosynthetic gene clusters (BGCs) contain a gene that has no role in SM biosynthesis
but, rather, encodes a resistant form of the protein inhibited by the compound produced by the cluster.
Expression of this gene makes the producing organism resistant to the compound it produces. We have
developed an approach, and computer application, that has allowed us to identify SM BGCs in the Joint
Genomes Institute database that we predict will produce compounds that inhibit two proteins that are essential
for fungal growth. They are FKS1, the catalytic subunit of an enzyme required for fungal cell wall biosynthesis,
and YEF3, a translation elongation factor found only in fungi. These proteins are not present in mammals and
inhibiting their activities should not be toxic to humans. Because expressing SMs in their native organisms is
usually very difficult, we propose to express representative BGCs predicted to produce FKS1 and YEF3 inhibitors
in the model fungus Aspergillus nidulans, which we have engineered for heterologous expression of fungal SMs.
We propose several approaches, building on our successes in this area, that we will evaluate for efficacy.
Heterologously expressed compounds will be purified and their structures will be determined. They will be tested
for activity against the pathogenic fungi Candida albicans and Cryptococcus neoformans as well as wild-type A.
nidulans which is a useful surrogate for pathogenic species of Aspergillus.
项目摘要
全世界每年约有150万人死于系统性真菌感染。高死亡人数
强调了目前治疗的局限性,此外,对
现有的抗真菌药物。因此,迫切需要新的和更好的抗真菌剂。令人惊讶的是,真菌
是抗真菌药的良好来源棘白菌素就是一个很好的例子真菌产生的抗真菌剂
是次级代谢物(SM)--对生存能力不是必需的,但具有选择性优势的化合物
对生产有机体,通常通过抑制其竞争对手的生长。事实上,他们往往抑制重要的
生物活性使它们成为有医学价值的化合物的主要来源。真菌SM生物合成
通路由协调调节的基因簇编码。基因组计划显示,
比已知的SM多得多的SM基因簇,因此,更大的真菌次级代谢组
(all由所有1,000,000+种真菌制成的SM)比以前认为的要大得多。开发
为了有效地研究真菌SM的多样性,我们需要能够识别产生具有所需结构的化合物的簇。
活动一种很有前途的方法,称为抗性基因导向的基因组挖掘,
事实上,一些SM生物合成基因簇(BGC)含有一个在SM生物合成中没有作用的基因,
而是编码一种被簇产生的化合物抑制的蛋白质的抗性形式。
该基因的表达使生产生物体对其产生的化合物具有抗性。我们有
开发了一种方法,和计算机应用程序,使我们能够识别SM BGC在联合
基因组研究所数据库,我们预测将产生化合物,抑制两种蛋白质是必不可少的
供真菌生长。它们是FKS 1,真菌细胞壁生物合成所需的酶的催化亚基,
和YEF 3,一种仅在真菌中发现的翻译延伸因子。这些蛋白质不存在于哺乳动物中,
抑制它们的活性不应该对人类有毒。因为在它们的原生生物体中表达SM,
通常非常困难,我们建议表达预测产生FKS 1和YEF 3抑制剂的代表性BGC
在模型真菌构巢曲霉中,我们已经将其工程化用于真菌SM的异源表达。
我们提出了几种方法,建立在我们在这一领域的成功,我们将评估其有效性。
将纯化异源表达的化合物并确定其结构。他们将接受考验
对致病真菌白色念珠菌和新型隐球菌以及野生型A.
nidulans,其是曲霉属致病性物种的有用替代物。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Manipulation of the Global Regulator mcrA Upregulates Secondary Metabolite Production in Aspergillus wentii Using CRISPR-Cas9 with In Vitro Assembled Ribonucleoproteins.
- DOI:10.1021/acschembio.2c00456
- 发表时间:2022-10-21
- 期刊:
- 影响因子:4
- 作者:Yuan, Bo;Keller, Nancy P.;Oakley, Berl R.;Stajich, Jason E.;Wang, Clay C. C.
- 通讯作者:Wang, Clay C. C.
Conversion of Polyethylenes into Fungal Secondary Metabolites.
- DOI:10.1002/anie.202214609
- 发表时间:2023-01-23
- 期刊:
- 影响因子:16.6
- 作者:Rabot, Chris;Chen, Yuhao;Bijlani, Swati;Chiang, Yi-Ming;Oakley, C. Elizabeth;Oakley, Berl R.;Williams, Travis J.;Wang, Clay C. C.
- 通讯作者:Wang, Clay C. C.
Computer-aided, resistance gene-guided genome mining for proteasome and HMG-CoA reductase inhibitors.
- DOI:10.1093/jimb/kuad045
- 发表时间:2023-02-17
- 期刊:
- 影响因子:3.4
- 作者:
- 通讯作者:
Identification of the chaA and fwA Spore Color Genes of Aspergillus nidulans.
构巢曲霉 chaA 和 fwA 孢子颜色基因的鉴定。
- DOI:10.3390/jof10020104
- 发表时间:2024
- 期刊:
- 影响因子:0
- 作者:Oakley,CElizabeth;BartonJr,ThomasS;Oakley,BerlR
- 通讯作者:Oakley,BerlR
A heterologous expression platform in Aspergillus nidulans for the elucidation of cryptic secondary metabolism biosynthetic gene clusters: discovery of the Aspergillus fumigatus sartorypyrone biosynthetic pathway.
- DOI:10.1039/d3sc02226a
- 发表时间:2023-10-18
- 期刊:
- 影响因子:8.4
- 作者:Lin, Shu-Yi;Oakley, C. Elizabeth;Jenkinson, Cory B.;Chiang, Yi-Ming;Lee, Ching-Kuo;Jones, Christopher G.;Seidler, Paul M.;Nelson, Hosea M.;Todd, Richard B.;Wang, Clay C. C.;Oakley, Berl R.
- 通讯作者:Oakley, Berl R.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BERL Ray OAKLEY其他文献
BERL Ray OAKLEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BERL Ray OAKLEY', 18)}}的其他基金
Mining the aspergillus nidulans secondary metabolome
挖掘构巢曲霉次级代谢组
- 批准号:
7813486 - 财政年份:2009
- 资助金额:
$ 19.14万 - 项目类别:
Mining the Aspergillus nidulans Secondary Metabolome
挖掘构巢曲霉次级代谢组
- 批准号:
7837747 - 财政年份:2008
- 资助金额:
$ 19.14万 - 项目类别:
Mining the Aspergillus nidulans Secondary Metabolome
挖掘构巢曲霉次级代谢组
- 批准号:
8073833 - 财政年份:2008
- 资助金额:
$ 19.14万 - 项目类别:
Mining the Aspergillus nidulans Secondary Metabolome
挖掘构巢曲霉次级代谢组
- 批准号:
8314135 - 财政年份:2008
- 资助金额:
$ 19.14万 - 项目类别:
Mining the Aspergillus nidulans Secondary Metabolome
挖掘构巢曲霉次级代谢组
- 批准号:
7670732 - 财政年份:2008
- 资助金额:
$ 19.14万 - 项目类别:
Mining the Aspergillus nidulans Secondary Metabolome
挖掘构巢曲霉次级代谢组
- 批准号:
8071184 - 财政年份:2008
- 资助金额:
$ 19.14万 - 项目类别:
Molecular Genetic Mining of the Aspergillus Nidulans Secondary Metabolome
构巢曲霉次生代谢组的分子遗传学挖掘
- 批准号:
7501700 - 财政年份:2008
- 资助金额:
$ 19.14万 - 项目类别:
Mining the Aspergillus nidulans Secondary Metabolome
挖掘构巢曲霉次级代谢组
- 批准号:
7440723 - 财政年份:2008
- 资助金额:
$ 19.14万 - 项目类别:
Mining the Aspergillus nidulans Secondary Metabolome
挖掘构巢曲霉次级代谢组
- 批准号:
7619270 - 财政年份:2008
- 资助金额:
$ 19.14万 - 项目类别:
MOLECULAR BIOLOGY OF MICROTUBULE INTERACTING PROTEINS
微管相互作用蛋白的分子生物学
- 批准号:
2176336 - 财政年份:1983
- 资助金额:
$ 19.14万 - 项目类别:
相似海外基金
ESE: Collaborative Research: Climate Change and Variability and Armed Conflicts in Africa South of the Sahara
ESE:合作研究:撒哈拉以南非洲的气候变化和变异性以及武装冲突
- 批准号:
0964515 - 财政年份:2010
- 资助金额:
$ 19.14万 - 项目类别:
Standard Grant
Network Dynamics, Sexual Behaviour, and HIV Among University Students in Africa South of the Sahara
撒哈拉以南非洲大学生的网络动态、性行为和艾滋病毒
- 批准号:
178094 - 财政年份:2008
- 资助金额:
$ 19.14万 - 项目类别:
Studentship Programs
Synopsis of Ichneumoniae of Africa, South of the Sahara
撒哈拉以南非洲的姬蜂病简介
- 批准号:
66B2956 - 财政年份:1966
- 资助金额:
$ 19.14万 - 项目类别:
To Attend Synopsis of Ichneumoninae of Africa, South of the Sahara
参加撒哈拉以南非洲的姬蜂亚科概要
- 批准号:
65B2956 - 财政年份:1965
- 资助金额:
$ 19.14万 - 项目类别: